Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Shimon Ben Shabat

Raphael Mechoulam

Aviva Breuer

Amnou Sintov

Tzviel Sheskin

Esther Fride

Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases and disorders.

Substituted cyclohexylidene-ethylidene-octahydro-indene compounds

The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.

Synthetic endogenous cannabinoids analogues and uses thereof

Growing community of inventors

Jerusalem, Israel

Shimon Ben Shabat